Rockville, US [March 15, 2018] BioTel Research, with support from AMRA, has published a new White Paper with industry insights about the imaging modalities that are rapidly gaining ground as the new norm for NAFLD/NASH diagnosis and evaluation in a clinical trial setting. The paper includes an insight into the use of AMRA’s automated analysis of rapid, whole-body MRI and precise body composition measurements for describing a patient’s metabolic journey through the NAFLD/NASH spectrum. Read more about the BioTel Research — AMRA partnership and how advanced liver imaging and automated body composition assessments can be used to optimize your clinical trial.
Download the white paper: Click here